DPP4, also known as CD26 or adenosine deaminase complexing protein 2, is a membrane-associated peptidase that is largely distributed in a number of tissues.
DPP4 in Different Functions
This promiscuous enzyme has been stated to be involved in a range of different functions such as co-stimulation throughout T cell activation, migration and invasion of endothelial cells into collagenous matrices, adenosine deaminase binding, cell matrix adhesion, and interaction with human immunodeficiency virus (HIV) proteins. A key role of DPP4 is to regulate the glucose metabolism.
It degrades the incretin hormones like glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP). These hormones are associated with the regulation of insulin and have a number of anti-diabetic actions, including enhancement of meal stimulated insulin secretion, decreased glucagon secretion, enhancements in β cell function etc.
DPP4 Inhibitors for Treating Type 2 Diabetes
Inhibiting DPP4 activity by DPP4 inhibitors stops the inactivation and prolongs the duration of action of these incretin hormones, which then, aid to correct the defective insulin and glucagons secretion that marks type 2 diabetes. In 2006 the first DPP-4 inhibitor, sitagliptin, became available as a way of treating type 2 diabetes.
DPP-4 inhibitors have become an important drug class to treat type 2 diabetes since then. BioVision offers a wide scope of DPP4 related products including inhibitors, signal transduction, apoptosis, assay kits, antibodies and recombinant proteins for researchers pursuing research in the area of diabetes, inflammation and immune regulation.
About BioVision Incorporated
BioVision, Inc., is a privately held Life Science company headquartered in the beautiful San Francisco Bay Area.
BioVision develops and offers a wide variety of products including assay kits, antibodies, recombinant proteins & enzymes, and other innovative research tools for studying Apoptosis, Metabolism, Cell Proliferation, Cellular Stress, Cell Damage and Repair, Diabetes, Obesity and Metabolic Syndrome, Stem Cell Biology, Gene Regulation, Signal Transduction, etc. BioVision's products are currently being sold in more than 60 countries worldwide.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.